Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
Aptorum Group (NASDAQ: APM) has received a notification from Nasdaq Stock Market on April 15, 2025, regarding non-compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2).
The company has been granted a 180-calendar-day grace period until October 14, 2025, to regain compliance with the listing requirements. During this period, the trading of APM shares on Nasdaq will continue unaffected.
To address this situation, Aptorum Group is evaluating various options, including the possibility of implementing a reverse stock split. The biotechnology company has expressed its commitment to maintaining its Nasdaq listing and will pursue necessary measures to achieve compliance within the specified timeframe.
Positive
- 180-day grace period granted to regain compliance
- Trading continues unaffected during compliance period
Negative
- Stock price has fallen below $1, triggering Nasdaq minimum bid price compliance issues
- Potential reverse stock split may be necessary to maintain listing
- Risk of delisting from Nasdaq if compliance is not achieved by October 14, 2025
News Market Reaction – APM
On the day this news was published, APM declined 15.29%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of
The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements.
During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
About Aptorum Group Limited
Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For further information, please contact: investor.relations@aptorumgroup.com
FAQ
What is the deadline for Aptorum Group (APM) to regain Nasdaq compliance?
What is the minimum share price requirement that APM needs to meet for Nasdaq compliance?
Will APM stock continue trading on Nasdaq during the compliance period?
What solutions is Aptorum Group (APM) considering to address the Nasdaq compliance issue?
